Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 11/20 | 0.60 |
| ▸ | F10 | P00742 | 10/20 | 0.60 |
| ▸ | F7 | P08709 | 3/20 | 0.60 |
| ▸ | PLAU | P00749 | 9/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.52 |
| ▸ | PLG | P00747 | 8/20 | 0.51 |
| ▸ | PLAT | P00750 | 6/20 | 0.51 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30882714 | 0.99 | KDM4E (0.59) | KDM4ENPC1ALDH1A1TP53PKM | |
| Hydrochloric Acid SCHEMBL23201170 | 0.99 | KDM4E (0.59) | KDM4ENPC1ALDH1A1TP53PKM | |
| SCHEMBL23775703 | 0.87 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23775706 | 0.86 | PLAU (0.51) | F2F10F7PLAUPRSS1 | |
| SCHEMBL2077857 | 0.85 | F2 (0.60) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23793907 | 0.84 | F2 (0.83) | KDM4ENPC1ALDH1A1TP53PKM | |
| SCHEMBL7410247 | 0.83 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL6162198 | 0.81 | F10 (0.56) | F2F10F7PLAUPRSS1 | |
| SCHEMBL6161244 | 0.81 | F2 (0.81) | KDM4ENPC1TP53PKMHPGD | |
| SCHEMBL7408233 | 0.81 | F2 (0.55) | F2F10F7PLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-0943008-B1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6355460-B1 | DETECTING ENZYME INHIBITORS; INCUBATE ENZYME WITH MODULATOR, MONITOR SAMPLE FOR REDUCTION IN ENZYME ACTIVITY, REDUCTION IN ENZYME ACTIVITY INDICATES MODULATOR | AXYS PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | disclosed |
| US-6255091-B1 | ASSAYING FOR ENHANCED INHIBITION OF SERINE PROTEASE IN A MEDIUM THAT IS DEVOID OF DISSACIATED DIVALENT METAL CATIONS | AXYS PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0943008-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022619-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KDM4E 4128/4885NPC1 2300/4885ALDH1A1 4701/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4128/4885NPC1 2300/4885ALDH1A1 4701/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | KDM4E 1186/4885NPC1 4843/4885ALDH1A1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.